Insulet Extends Partnership with Glooko in Europe to Optimise Diabetes Data Management

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global
leader in tubeless
insulin pump technology with its Omnipod® Insulin
Management System (Omnipod System), today announced that it has
partnered with Glooko®, Inc. to connect Insulet’s Omnipod
System user data with Glooko+diasend®, the most comprehensive
diabetes data management system available, across Europe.

“Insulet and Glooko are dedicated to bringing innovation to diabetes
management around the world. We are delighted to work together to
provide Omnipod users across Europe the ability to remotely sync data
from their Omnipod Systems using Glooko+diasend,” said DJ Cass, General
Manager, Insulet Europe. “This combined platform makes their lives
easier by allowing people with diabetes to review their blood glucose
patterns on their smartphones and monitor the impact of their insulin
regimen, diet and physical activity on their diabetes management.”

Insulet’s partnership with Glooko is further proof of its commitment to
putting customers first, as it ensures Insulet can continue to be closer
to the diabetes community and provide personalised support for Podders™
across Europe.

“Glooko has a long-standing relationship with Insulet and we are very
excited to now expand our collaboration even further within the European
markets,” said Anders Sonesson, General Manager Glooko Europe. “We are
proud to support the Omnipod System with our universal data management
solution and our seamless user experience will appeal to numerous health
care providers and their patients throughout Europe, taking clinic
workflow, remote patient monitoring and overall diabetes treatment plans
to new heights.”

Glooko+diasend is currently used at approximately 7,000 provider sites
by over 1.5 million users in 23 countries, and the system is offered in
15 languages.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is
an innovative medical device company dedicated to making the lives of
people with diabetes and other conditions easier through the use of its
Omnipod product platform. The Omnipod Insulin Management System provides
a unique alternative to traditional insulin delivery methods. With its
simple, wearable design, the disposable Pod provides up to three days of
non-stop insulin delivery, without the need to see or handle a
needle. Insulet also leverages the unique design of its Pod, by
tailoring its Omnipod technology platform for the delivery of
non-insulin subcutaneous drugs across multiple therapeutic areas.
Founded in 2000, more than 140,000 users across the globe rely on
Insulet’s Omnipod Insulin Management System to bring simplicity and
freedom to their lives.

On July 1, 2018, Insulet assumed direct operations of its Omnipod
Insulin Management System product line in Europe, including sales,
marketing, training and customer support activities. This allows Insulet
to be closer to the diabetes community and identify opportunities to
support European customer needs over the long-term, as Insulet does in
the United States and Canada.

For more information, please visit:

About Glooko:

Glooko provides insights into diabetes by enabling both people with
diabetes (PWDs) and their care teams with technology to understand and
manage diabetes care. With Glooko, one can easily upload data from more
than 160 devices such as blood glucose meters, insulin pumps, CGMs and
several fitness and activity trackers — providing timely and verified
data and enabling PWDs and care teams to correlate it with diet,
exercise, medication and other data. Glooko provides care teams with an
easy office data upload solution and a population health app so they can
support PWDs during and in-between office visits. Trusted by the world’s
leaders in diabetes care, Glooko is used by 7,000 clinics and over 1.5
million PWDs in 23 countries across 15 languages. Learn more by visiting

Forward-Looking Statement:

This press release may contain forward-looking statements
concerning Insulet’s expectations, anticipations, intentions, beliefs or
strategies regarding the future. These forward-looking statements are
based on its current expectations and beliefs concerning future
developments and their potential effects on Insulet. There can be no
assurance that future developments affecting Insulet will be those that
it has anticipated. These forward-looking statements involve a number of
risks, uncertainties (some of which are beyond its control) or other
assumptions that may cause actual results or performance to be
materially different from those expressed or implied by these
forward-looking statements, and other risks and uncertainties described
in its Annual Report on Form 10-K, which was filed with the Securities
and Exchange Commission on February 22, 2018 in the section entitled
“Risk Factors,” and in its other filings from time to time with
the Securities and Exchange Commission. Should one or more of these
risks or uncertainties materialize, or should any of its assumptions
prove incorrect, actual results may vary in material respects from those
projected in these forward-looking statements. Insulet undertakes no
obligation to publicly update or revise any forward-looking statements.

© 2018 Insulet Corporation. Omnipod, the Omnipod logo and Podders are
trademarks or registered trademarks of Insulet Corporation. All rights
reserved. Glooko and diasend are trademarks of Glooko, Inc. and used
with permission.

View source version on

Leave a Comment